MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives

Figure 2

Contrast-enhanced T1-weighted images (a–f) and the calculated TRAM postchemoradiation (g–l) (images were acquired 0.7, 2.5, 4, 6, 7, and 8 months postchemoradiation). Temporary enlargement of enhancing lesion (c-d) is shown; as it can be seen, the red volume growth rate was prevalent above the blue volume (i-j), favoring pseudoprogression over progression. Pseudoprogression was later confirmed by the decrease in all volumes 7 and 8 months postchemoradiation (e-f, k-l). Modified from [110] with permission.